Axsome Therapeutics Inc. (AXSM) stock coverage started with “Buy” at Brean Capital

Axsome Therapeutics Inc. (NASDAQ: AXSM) shares rose in early trading today on lower trade volume than normal after more analysts initiated coverage on the stock.

Analysts at Brean Capital initiated coverage on Axsome Therapeutics Inc. (NASDAQ: AXSM) stock, starting the company at Buy. Brean Capital currently has a rating of Buy on the stock. The one-year price target of $23.33 is higher than the opening price of $7.85, resulting a fair amount of other analysts to issue statements on the company in recent days. Looking back over the last 52 weeks, Axsome Therapeutics Inc. stock has a high of $15.74. Analysts and brokerage firms will subsequently re periodic updates after initiating coverage,. Price changes targets are not uncommon.

Meanwhile, US stock opened lower amid concerns surrounding the U.S. Department of Justice’s probe into Deutsche Bank AG.

The S&P 500 SPX, -0.25% slipped 5 points, or 0.2%, to 2,162.

The Dow industrials DJIA, -0.26% fell 55 points, or 0.3%, to 18,252.

The Nasdaq Composite COMP, -0.11% was off 13 points, or 0.3%, to 5,298

Shares of Axsome Therapeutics Inc. (NASDAQ: AXSM) opened at $7.85 yesterday trading between $7.85 and $8.00, and last traded at $7.98, which represents a spike of $0.10 or 0.01 over the previous closing price.

Axsome Therapeutics Inc. (NASDAQ: AXSM) currently has a market cap of 152.81M.

Axsome Therapeutics Inc.Trading Volume

5,317 shares crossed the trading desk yesterday, below the norm, out of a total float 11,131,000. Look for trading volume to pick up in the coming days as investors often use increases in trading volume to determine large volume growth or dissemination by institutional investors.

As with all possible breakouts, investors look for volume to be at least 40%-50% above normal on the breakout to indicate that fund managers and other professional investors are jumping in.

Institutional sponsorship commonly refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these have teams of analysts that research thousands of stocks, so it is good confirmation to see them taking a postion in a stock you are considering.

Axsome Therapeutics Inc. Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

Traders are able to make make educated trades when they follow the trading habits of professional investors.

Trades for Axsome Therapeutics Inc. (NASDAQ: AXSM) have ranged from $5.37 – 15.74, and the stock now has a 50-day MA of $7.44 and 200-day MA of $8.44. Today’s last price is 0.49% lower than the 52 week high of $15.74.

Earnings growth is a crucial factor to research when buying stocks and investors seek companies that have grown their earnings by at least 25% for 3 consecutive years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *